Serpin Pharma and Uniklinikum Erlangen Launch AKI Prevention Clinical Trial

Serpin Pharma has collaborated with Uniklinikum Erlangen to conduct a Phase IIa clinical trial evaluating SP163M, a new therapeutic designed to prevent acute kidney injury (AKI) in patients with stage 2-3 chronic kidney disease (CKD) undergoing cardiac surgery. This trial seeks to assess the efficacy and safety of SP163M, with nephrologists Prof. Dr. Mario Schiffer and Dr. Tilman Jobst-Schwan leading the study.

The collaboration combines Serpin Pharma’s expertise in developing innovative therapeutics with Uniklinikum Erlangen’s clinical research capabilities. SP163M is designed to target specific receptors to help restore cellular balance during inflammation, a critical factor in preventing AKI. The trial, known as EASE-AKI, will use KDIGO criteria to evaluate the treatment’s effectiveness and safety. The trial is expected to advance the understanding of AKI prevention and potentially reduce healthcare costs associated with kidney injuries during cardiac surgeries.